Agilent Technologies is expanding its involvement in diagnostics with the acquisition of research equipment company Seahorse Bioscience. The $235 million cash deal should reportedly close by November.
Seahorse Bio’s XF Technology is used by thousands of scientists to research cell metabolism to better understand things like neurodegeneration, aging, cancer, cardiovascular disease and cell physiology.
The company’s XF Analyzers indicate mitochondrial respiration by measuring cells’ oxygen consumption rate and extracellular acidification rate, which can indicate cell death.
Solving Healthcare’s Provider Data Problem Starts with Interoperability
Break down the silos. Take control of your provider data.
“Seahorse Bioscience’s unique technology is the perfect complement to Agilent’s market-leading separations and mass spectrometry solutions, in particular for metabolomics research and disease research in pharma,” said Patrick Kaltenbach, the president of Agilent’s life sciences and applied markets group, according to Fierce Diagnostics. “The combination of these two platforms gives scientists a more comprehensive and faster path to researching the most challenging diseases affecting mankind. Seahorse’s team and technology are an ideal fit for Agilent and for our customers, and we look forward to bringing them on board.”
Jay Teich, CEO of Seahorse Bio reportedly said that he believes this partnership will allow the creation of new products. Almost all of Seahorse’s 200 employees will be transitioning over to Agilent.
Feature Photo: Flickr user Alex Griffioen